Navigation Links
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:4/8/2008

he improvements were achieved without any limiting next day cognitive effects. In both the Phase 1 program and the Phase 2a trial, APD125 was well tolerated at all doses investigated.

About APD125

Discovered by Arena, APD125 is a novel and oral selective inverse agonist of the 5-HT2A serotonin receptor. The vast majority of approved drugs for insomnia activate the GABA-A receptor complex in the brain, causing a general suppressive effect on the central nervous system, or CNS. These GABAergic drugs are generally associated with CNS side effects, including a sensation of dullness and lethargy upon awakening, often referred to as the "hangover effect." Other potential problems associated with the GABAergic drugs include the risk of developing tolerance and drug dependency in at-risk populations. In addition, GABAergic drugs are scheduled controlled substances by the Drug Enforcement Administration due to their potential for abuse.

By selectively targeting the 5-HT2A receptor, APD125 acts through a different mechanism than currently marketed insomnia drugs and blocks one of several CNS activating pathways. Because of the different mechanism of action, APD125 may not have the side effects or abuse potential generally associated with currently approved GABAergic drugs. Through its novel mechanism, APD125 has the potential to reduce insomnia symptoms by improving sleep maintenance.

About Insomnia

Insomnia is characterized by inadequate or poor sleep due to nonrefreshing sleep, frequent wakening with difficulty falling back to sleep, difficulty falling asleep or waking too early. Most insomnia complaints relate to sleep maintenance issues, such as waking frequently or awakening too early, as opposed to problems with sleep latency (i.e. falling asleep). About 30% of US adults report some level of insomnia in the course of a year, and about 10% of US adults indicate that their condition is chronic. In these cases, the lack of restful sleep i
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has announced the addition ... November 16-18, 2015)" conference to their offering. Regulatory requirements ... Columbia, Peru , Brazil , ... , Paraguay , Venezuela , ... Chile This seminar can be viewed both ...
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015  Seeger ... knee implant bellwether trial will commence October 13, 2015. ... 1995 using the 510K fast-track approval program, Zimmer NexGen ... The program only requires that companies provide evidence that ... approved product in order to gain permissions. ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 ... the addition of the "Medical Device Studies: ... conference to their offering. ... who are involved in gathering clinical evidence required ... data is required for all medical devices and ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... -- ADVANCE FOR RELEASE AT 5 P.M. EST MONDAY, ... Patients,who undergo complete prostate removal are less likely to ... done by an,experienced surgeon in a hospital that does ... the Agency for Healthcare Research and,Quality, part of the ...
... Regions of Body Consistent with Overall PASI ... Response in REMICADE-Treated Patients, SAN ANTONIO, ... placebo-controlled trials showed patients with moderate,to severe plaque psoriasis receiving ... each of the four body regions,(head, trunk, lower and upper ...
Cached Medicine Technology:Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior 2Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior 3Outcomes Vary for Prostate Cancer Patients Choosing Surgery; Overall, No Treatment Proven Superior 4REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 2REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 3REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 4REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 5REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 6REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 7REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 8REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 9REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body 10
(Date:9/2/2015)... KY (PRWEB) , ... September 02, 2015 , ... Ericson ... the CDI Education Director for HCPro and Associate Director of Education for the Association ... CDI, Advancing CDI and ICD-10 for CDI Boot Camps. She serves as a CDI ...
(Date:9/2/2015)... ... September 02, 2015 , ... The 2015 China Overseas ... investment and business conference will be hosted at five star Beijing Kunlun Hotel ... networking conference will feature leading EB-5 industry professionals and Chinese private equity partners ...
(Date:9/2/2015)... Minneapolis, MN (PRWEB) , ... September 02, 2015 ... ... is commercializing products for the upper extremity surgical market, announced today that more ... instrument for trigger releases in the hand. Plus, nearly 70 of these ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... On September ... to attend doTERRA’s annual convention, the largest single-company convention to date for the state ... and look forward to a tremendous event,” states David Stirling, doTERRA CEO. “One of ...
(Date:9/2/2015)... ... September 02, 2015 , ... The payroll conference ... days of payroll education covering legislative updates, including unemployment, global payroll best practices, ... representatives from Ceridian, Ultimate Software, the American Payroll Association, Barnett Associates, and the ...
Breaking Medicine News(10 mins):Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2
... indeed a ‘ubiquitous’ festival, as it is celebrated throughout the ... 26 million Indian homes.// The joys of the season is ... making the most of the special bargains and discounts of ... the celebration. Plans are afoot in great enthusiasm as homes ...
... The surprising structure and properties of a protein responsible for ... it binds its target RNA// -- are described by researchers ... is an essential nutrient, and defects in uptake and metabolism ... a variety of diseases and disorders, including heart disease, arthritis ...
... Agricultural Research Service (ARS) funded research suggest that berry extracts ... found that laboratory animals, which were fed berry extracts and ... damage to brain function. ,Three groups ... for about three months. The control group was fed a ...
... Health plans, school girls as young as 12 could ... cause cervical cancer//. Researchers have found that the Human ... of cervical cancer, which kills around 1,000 women a ... the human papilloma virus (HPV) before they become sexually ...
... (AL) on Saturday voiced concern on the developments regarding the ... Libyan children with the HIV/AIDS virus//. AL also issued an ... ,The AL also expressed full sympathy underlining the ... order to curb the consequences of this "painful human catastrophe". ...
... (FDA) is expected to announce soon the results of its ... some species of cloned animals. ,Two experts ... Agriculture Policy are available to media to comment on the ... safety of consuming meat and milk from cloned animals. ...
Cached Medicine News:Health News:Come Apart and Rest Awhile – It’s Christma 2Health News:Come Apart and Rest Awhile – It’s Christma 3Health News:Structure of Iron Regulatory Protein-RNA Complex Solved 2
... Vascular Graft, the newest vascular graft offering ... leader in vascular surgical products for more ... reducing kinking and compression problems that ... graft provides all of the benefits of ...
... rasping necessary in cruciate ligament reconstruction procedures ... bone surface. This condition, if not rectified ... cruciate replacement. The GORE SMOOTHER Crucial Tool ... procedures. The tool functions as both a ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
... system has been designed by practicing ... of the ever changing and demanding ... analyzing data from multiple modalities, including: ... and multiple patients at multiple sites. ...
Medicine Products: